Blue Jet Health

Which are the latest news on Blue Jet Health?

Why is Blue Jet Healthcare Ltd falling/rising?

As of 05-Sep, Blue Jet Healthcare Ltd's stock price is currently at 569.15, reflecting a decline of 1.73% and a total drop of 3.06% over the last three days. The stock has underperformed over the past year with a 19.70% decrease, amid reduced investor interest and negative sector performance.

As of 05-Sep, Blue Jet Healthcare Ltd's stock price is falling, currently at 569.15, which reflects a decrease of 10.0 or 1.73%. The stock has been on a downward trend, having lost value for the last three consecutive days, resulting in a total decline of 3.06% during this period. Additionally, the stock's performance over the past week shows a decline of 1.28%, which is slightly better than the benchmark Sensex's drop of 0.97%. <BR><BR>The stock has also underperformed over the past month, with a decrease of 2.21%, while the Sensex fell by 2.44%. Over the past year, Blue Jet Healthcare Ltd has experienced a significant decline of 19.70%, compared to the Sensex's smaller drop of 5.21%. <BR><BR>Today's trading activity indicates a low point for the stock, reaching an intraday low of Rs 563.25, which is a 2.75% decrease. Furthermore, there has been a notable drop in investor participation, with delivery volume falling by 48.32% compared to the five-day average. This decline in trading activity suggests reduced interest from investors, contributing to the stock's downward movement.<BR><BR>Despite these negative trends, it is worth noting that the company maintains a high management efficiency with a return on equity (ROE) of 22.58% and is net-debt free, which are positive factors for its long-term outlook. However, the current market conditions and sector performance, particularly in the Medical Equipment/Supplies/Accessories sector, which has fallen by 3.52%, are impacting the stock negatively at this time.

Who are in the management team of Blue Jet Health?

The management team of Blue Jet Health includes Akshay Bansarilal Arora (Executive Chairman), Shiven Akshay Arora (Managing Director), Naresh Suiyakant Shah (Executive Director), and several Independent Directors: Girish Paman Vanvari, Preeti Mehta, and Divya Momaya, along with Sweta Poddar as Company Secretary & Compliance Officer. They oversee the company's operations and strategic direction.

The management team of Blue Jet Health includes the following key members:<BR><BR>1. **Akshay Bansarilal Arora** - Executive Chairman<BR>2. **Shiven Akshay Arora** - Managing Director<BR>3. **Naresh Suiyakant Shah** - Executive Director<BR>4. **Girish Paman Vanvari** - Independent Director<BR>5. **Preeti Mehta** - Independent Director<BR>6. **Divya Momaya** - Independent Director<BR>7. **Sweta Poddar** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Blue Jet Health do?

Blue Jet Healthcare Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 293 Cr and a net profit of 78 Cr for June 2026. It was incorporated in 1968 and rebranded in 2022, with a market cap of INR 10,863 Cr.

Overview:<BR>Blue Jet Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The company was originally incorporated as Jet Chemicals Private Limited in 1968. It changed its name to Blue Jet Healthcare Private Limited in December 2020 and subsequently became a Limited Company, adopting the name Blue Jet Healthcare Limited on May 18, 2022. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 293 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 78 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 10,863 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 46.00 <BR>Industry P/E: 112 <BR>Dividend Yield: 0.19% <BR>Debt-Equity: -0.25 <BR>Return on Equity: 17.27% <BR>Price to Book: 8.05 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Blue Jet Health?

Blue Jet Health's peers include Jubilant Pharmo, Akums Drugs, Viyash Scientifi, Sanofi Consumer, P & G Health Ltd, Strides Pharma, Aarti Pharma, and Sanofi India. In terms of management risk, Blue Jet Health has a Good rating, while its 1-year return is -13.47%, better than Sanofi India's -39.16%.

Peers: The peers of Blue Jet Health are Jubilant Pharmo, Akums Drugs, Viyash Scientifi, Sanofi Consumer, P & G Health Ltd, Strides Pharma, Aarti Pharma, and Sanofi India.<BR><BR>Quality Snapshot: Excellent management risk is observed at Akums Drugs, Sanofi Consumer, P & G Health Ltd, and Sanofi India, while Good management risk is found at Blue Jet Health. Average management risk is present at Jubilant Pharmo, Strides Pharma, and Aarti Pharma, and the rest have Below Average management risk. Growth ratings show that Good growth is seen at Viyash Scientifi, Average growth at Akums Drugs and Strides Pharma, while Below Average growth is noted at Blue Jet Health, Jubilant Pharmo, Sanofi Consumer, P & G Health Ltd, Aarti Pharma, and Sanofi India. For Capital Structure, Excellent ratings are found at Akums Drugs, Blue Jet Health, Sanofi Consumer, P & G Health Ltd, and Aarti Pharma, while Average is seen at Jubilant Pharmo and Strides Pharma, and Below Average at Viyash Scientifi.<BR><BR>Return Snapshot: Akums Drugs has the highest 1-year return at 70.88%, while Sanofi India has the lowest at -39.16%. Blue Jet Health's 1-year return of -13.47% is better than Sanofi India but worse than Akums Drugs. Additionally, Sanofi Consumer, P & G Health Ltd, and Sanofi India have negative six-month returns.

How big is Blue Jet Health?

As of 31st August, Blue Jet Healthcare Ltd has a market capitalization of 10,863.00 Cr, with recent net sales of 885.67 Cr and a net profit of 234.91 Cr.

As of 31st August, Blue Jet Healthcare Ltd has a market capitalization of 10,863.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, Blue Jet Healthcare Ltd reported Net Sales of 885.67 Cr and a Net Profit of 234.91 Cr.<BR><BR>The latest annual period for the balance sheet is March 2021, with Shareholder's Funds amounting to 339.82 Cr and Total Assets of 536.27 Cr.

Are Blue Jet Healthcare Ltd latest results good or bad?

Blue Jet Healthcare Ltd's latest results show strong quarter-on-quarter growth, with revenue up 24.90% and net profit up 21.64%. However, year-on-year declines in both metrics raise concerns about the company's long-term growth prospects.

Blue Jet Healthcare Ltd's latest results present a mixed picture. On the positive side, the company achieved a significant quarter-on-quarter improvement in both revenue and net profit for Q1 FY27. Revenue increased by 24.90% to ₹293.11 crore, while net profit rose by 21.64% to ₹78.26 crore. Additionally, operating margins improved to 33.46%, reflecting better operational efficiency.<BR><BR>However, the year-on-year comparisons reveal a concerning trend. Both revenue and net profit declined compared to the same quarter last year, with revenue down 17.38% and net profit down 14.14%. This marks the third consecutive quarter of year-on-year revenue decline, indicating potential structural challenges that the company may need to address.<BR><BR>Overall, while the sequential growth is encouraging, the persistent year-on-year declines raise questions about the sustainability of this recovery and the company's growth trajectory moving forward. Investors should be cautious and monitor how management plans to tackle these ongoing challenges.

Should I buy, sell or hold Blue Jet Healthcare Ltd?

When is the next results date for Blue Jet Healthcare Ltd?

The next results date for Blue Jet Healthcare Ltd is August 3, 2026.

The next results date for Blue Jet Healthcare Ltd is scheduled for August 3, 2026.

Is Blue Jet Health overvalued or undervalued?

As of November 25, 2025, Blue Jet Health is considered very expensive and overvalued, with a PE ratio of 27.80 and lagging behind the Sensex with a year-to-date return of -0.49%.

As of 25 November 2025, Blue Jet Health's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 27.80, an EV to EBIT of 22.46, and a Price to Book Value of 7.80, all of which suggest a high valuation relative to earnings and asset value.<BR><BR>In comparison to its peers, Blue Jet Health's valuation metrics are notably elevated; for instance, Poly Medicure has a PE ratio of 53.35 and an EV to EBITDA of 40.61, while Vimta Labs shows a PE of 44.86 and an EV to EBITDA of 24.04, both categorized as very expensive. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -0.49% compared to the Sensex's 8.25%, reinforcing the notion of overvaluation.

Is Blue Jet Health technically bullish or bearish?

As of November 3, 2025, Blue Jet Health's technical trend has shifted to a moderately bearish stance, indicated by a bearish MACD, moving averages, and Bollinger Bands, suggesting a negative outlook in the near term.

As of 3 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Blue Jet Health is bearish with a moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a mildly bearish reading on the weekly Bollinger Bands. Additionally, the Dow Theory indicates a mildly bearish trend on the weekly chart. Overall, the combination of these indicators suggests a negative outlook for the stock in the near term.

How has been the historical performance of Blue Jet Health?

Blue Jet Health experienced a decline in net sales and profit from March 2020 to March 2021, with net sales dropping to 498.93 Cr from 538.20 Cr and profit after tax decreasing to 135.79 Cr from 144.96 Cr. Despite this, the company saw an increase in total assets and a significant rise in cash inflow.

Answer:<BR>The historical performance of Blue Jet Health shows a decline in net sales and profit from March 2020 to March 2021.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2021, Blue Jet Health reported net sales of 498.93 Cr, down from 538.20 Cr in the previous year. Total operating income also decreased to 498.93 Cr from 538.20 Cr. The raw material cost rose to 214.27 Cr from 186.60 Cr, while the total expenditure, excluding depreciation, fell to 292.88 Cr from 324.47 Cr. Operating profit (PBDIT) decreased slightly to 214.93 Cr from 219.54 Cr, and profit before tax declined to 184.66 Cr from 194.13 Cr. Consequently, profit after tax also dropped to 135.79 Cr from 144.96 Cr. The earnings per share (EPS) saw a significant reduction, falling to 27.4 from 483.2. On the balance sheet, total liabilities increased to 536.27 Cr from 373.85 Cr, while total assets rose to 536.27 Cr from 373.85 Cr. The company experienced a net cash inflow of 51.00 Cr in March 2021, compared to 5.00 Cr in March 2020, with closing cash and cash equivalents increasing to 61.00 Cr from 10.00 Cr.

Who are the top shareholders of the Blue Jet Health?

The top shareholder of Blue Jet Health is Akshay Bansarilal Arora, holding 68.99%. Other shareholders include mutual funds at 0.5%, foreign institutional investors at 1.97%, and individual investors with a collective holding of 8.03%.

The top shareholders of Blue Jet Health include the promoters, with Akshay Bansarilal Arora being the individual with the highest holding at 68.99%. Additionally, the company has mutual funds holding 0.5% through 8 schemes and foreign institutional investors (FIIs) holding 1.97% across 53 FIIs. Individual investors collectively hold 8.03% of the shares. There are no significant public shareholders listed.

Has Blue Jet Health declared dividend?

Yes, Blue Jet Healthcare Ltd has declared a 50% dividend, amounting to 1 per share, with an ex-date of September 17, 2024. While the company has shown strong price returns of 80.89% over the last six months and 141.24% over the past year, dividend returns remain minimal.

Blue Jet Healthcare Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 1 per share<BR>- Ex-date: 17 Sep 24<BR><BR>Dividend Yield: 0.11%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 80.89%, with no dividend return, resulting in a total return of 80.89%.<BR><BR>Over the past year, the price return reached 141.24%, with a dividend return of 0.27%, leading to a total return of 141.51%.<BR><BR>For the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, there were no price or dividend returns, leading to a total return of 0.0%.<BR><BR>For the 4-year period, the price return and dividend return were both 0%, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Blue Jet Healthcare Ltd has declared a dividend, the company has shown significant price returns over the past year and six months, but the dividend returns have been minimal in comparison.